1.65
+0.05(+3.13%)
Currency In USD
| Previous Close | 1.6 |
| Open | 1.59 |
| Day High | 1.72 |
| Day Low | 1.59 |
| 52-Week High | 14.8 |
| 52-Week Low | 0.77 |
| Volume | 293,129 |
| Average Volume | 482,195 |
| Market Cap | 24.48M |
| PE | -0.29 |
| EPS | -5.62 |
| Moving Average 50 Days | 2.02 |
| Moving Average 200 Days | 2.28 |
| Change | 0.05 |
If you invested $1000 in Longeveron Inc. (LGVN) since IPO date, it would be worth $22.27 as of December 22, 2024 at a share price of $1.65. Whereas If you bought $1000 worth of Longeveron Inc. (LGVN) shares 2 years ago, it would be worth $58.72 as of December 22, 2024 at a share price of $1.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Longeveron to Present at Biotech Showcase 2025
GlobeNewswire Inc.
Dec 18, 2024 2:10 PM GMT
MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’e
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
GlobeNewswire Inc.
Dec 02, 2024 2:05 PM GMT
MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it w
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
GlobeNewswire Inc.
Nov 11, 2024 2:05 PM GMT
MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it h